Autoimmune Gastrointestinal Dysmotility Market Growth Is Accelerating As Industry Transformation Continues
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Autoimmune Gastrointestinal Dysmotility Market Expansion From $1.91 Billion In 2026 To $2.62 Billion In 2030
The market for autoimmune gastrointestinal dysmotility has seen robust expansion in recent times. Projected to rise in value from $1.82 billion in 2025 to $1.92 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 5.5%. Factors driving the historical period’s expansion include an increase in the diagnosis of autoimmune diseases, a higher prevalence of gastroparesis, the broadening of hospital gastroenterology services, a greater utilization of immunosuppressive medications, and heightened awareness regarding rare diseases.
The market for autoimmune gastrointestinal dysmotility is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $2.63 billion, reflecting a compound annual growth rate (CAGR) of 8.2%. This forecasted growth is driven by advancements in early diagnosis, the adoption of personalized treatment strategies, a rising need for long-term care, the increasing use of home-based nutrition therapy, and the broadening scope of autoimmune research. Key trends shaping this period include a heightened awareness of rare gastrointestinal conditions, a greater reliance on immunosuppressive therapies, an expanded focus on nutritional and dietary interventions, the growing implementation of multidisciplinary care models, and an emphasis on sustained symptom management.
Download A Free Sample Report For Comprehensive Market Insights:
Autoimmune Gastrointestinal Dysmotility Market Demand Drivers: What Is Fueling Industry Growth?
The growing number of clinical trials is set to drive the expansion of the autoimmune gastrointestinal dysmotility market in the coming period. These trials involve research investigations that assess the safety, effectiveness, and best use of medical interventions including pharmaceuticals, biologics, devices, and treatment regimens in human subjects, all aimed at advancing medical understanding and enhancing patient outcomes. This rise in clinical activities stems from broader regulatory mandates for trial registration, heightened investment in pharmaceutical research and development, and the swift pace of innovation in novel therapeutic strategies like immunotherapies and biologics designed to address autoimmune conditions affecting gut motility. Trials focused on autoimmune gastrointestinal dysmotility enhance therapeutic options through the systematic evaluation of new immunosuppressants, prokinetic agents, and biologics; they help determine ideal treatment protocols for handling motility disorders and build evidence-based frameworks that facilitate regulatory approvals and clinical integration of innovative therapies targeting immune-mediated gastrointestinal impairment. For example, in November 2025, data from ClinicalTrials.gov, a U.S.-based clinical trial registry run by the National Institutes of Health, showed that the total count of registered clinical studies was 477,203 at the close of 2023 (including 437,493 cumulative and 39,710 new entries) and climbed to 520,877 by the end of 2024 (which comprised 477,203 cumulative and 43,674 new entries), indicating a 9.1% year-over-year growth in overall registered investigations. Consequently, the rising number of clinical trials is fueling the advancement of the autoimmune gastrointestinal dysmotility market.
A heightened emphasis on personalized medicine is anticipated to accelerate growth in the autoimmune gastrointestinal dysmotility market moving forward. This medical strategy tailors therapeutic and preventive approaches to an individual’s distinct genetic profile, lifestyle, and environmental factors. The growing adoption of personalized medicine largely results from progress in genomics, which allows for accurate detection of genetic variations and the development of customized treatments for patients. In managing autoimmune gastrointestinal dysmotility, personalized medicine customizes therapies according to a patient’s genetic background and specific disease features, thereby boosting treatment effectiveness while reducing adverse effects. This delivers more precise options for addressing complex gastrointestinal disorders. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a nonprofit organization based in the U.S., reported that the U.S. Food and Drug Administration (FDA) authorized 26 new personalized medicines in 2023, a notable jump from the 12 approvals recorded in 2022. Therefore, the intensified focus on personalized medicine is propelling the autoimmune gastrointestinal dysmotility market forward.
An increasing incidence of autoimmune disorders is forecast to stimulate the autoimmune gastrointestinal dysmotility market in the near future. Autoimmune diseases occur when the immune system erroneously attacks healthy cells, tissues, or organs within the body, rather than defending them against infections and external threats. This rise is mainly attributed to a mix of genetic predisposition and environmental triggers that collectively impair immune system regulation, raising the chance that the body will target its own tissues. Autoimmune gastrointestinal dysmotility aids in detecting and managing underlying autoimmune conditions by uncovering immune-mediated harm to the enteric nervous system and associating gastrointestinal symptoms with broader systemic autoimmune activity. For example, in October 2024, a thorough review published in Signal Transduction and Targeted Therapy, a peer-reviewed scientific journal by Nature in the UK, noted that roughly 8.4 million individuals globally suffer from rheumatoid arthritis, with the overall incidence rate rising by 2-3% each year; projections using the Markov model suggest that affected populations could reach between 13.5 and 17.4 million by 2040. Hence, the growing prevalence of autoimmune disorders is accelerating the expansion of the autoimmune gastrointestinal dysmotility market.
Autoimmune Gastrointestinal Dysmotility Market Segments: Where Are The Largest Growth Opportunities?
The autoimmune gastrointestinal dysmotility market covered in this report is segmented –
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs)
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
Autoimmune Gastrointestinal Dysmotility Market Major Participants And Competitive Dynamics
Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
Access The Complete Autoimmune Gastrointestinal Dysmotility Market Report:
Autoimmune Gastrointestinal Dysmotility Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2025. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
